Phase I Studies Drive 16% Rise In Danish Clinical Trial Applications
Executive Summary
Clinical trial applications in Denmark rose by just under 16% in 2015, driven partly by a doubling in the number of Phase I studies, which the medicines agency attributes to the work of a new public-private partnership aimed at boosting Denmark’s attractiveness as a location for early-phase trials.
You may also be interested in...
Danish GCP Inspectors Get Full Access To Electronic Patient Data
Changes to the Danish clinical trials legislation will ensure that GCP inspectors, who were earlier denied direct access with their own username and password to electronic health records of trial subjects, now have full access to this information while inspecting studies.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.